At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
400
Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
Department and Institute of Infectious Disease
Wuhan, Hubei, China
RECRUITINGRate of disease remission
A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2\> 93% or PaO2/FiO2\>300mmHg (1mmHg=0.133Kpa);
Time frame: two weeks
Time for lung recovery
Compare the average time of lung imaging recovery after 2 weeks of treatment in each group.
Time frame: two weeks
Rate of no fever
Time frame: two weeks
Rate of respiratory symptom remission
Time frame: two weeks
Rate of lung imaging recovery
Time frame: two weeks
Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery
Time frame: two weeks
Rate of undetectable viral RNA
Time frame: two weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.